Seaport Res Ptn Analysts Raise Earnings Estimates for HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) – Investment analysts at Seaport Res Ptn increased their Q1 2025 EPS estimates for shares of Hims & Hers Health in a research report issued to clients and investors on Monday, February 24th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will post earnings per share of $0.12 for the quarter, up from their previous estimate of $0.08. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s Q2 2025 earnings at $0.15 EPS, Q3 2025 earnings at $0.18 EPS and Q4 2025 earnings at $0.19 EPS.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%.

Several other equities research analysts have also recently weighed in on HIMS. Leerink Partners increased their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, Truist Financial raised their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $34.47.

Hims & Hers Health Stock Up 5.0 %

Shares of HIMS opened at $41.87 on Wednesday. The stock has a market capitalization of $9.15 billion, a P/E ratio of 95.15 and a beta of 1.35. The firm has a fifty day simple moving average of $35.89 and a two-hundred day simple moving average of $26.36. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Crewe Advisors LLC bought a new stake in Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. increased its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its stake in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth approximately $38,000. 63.52% of the stock is currently owned by institutional investors.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 33,513 shares of Hims & Hers Health stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $1,118,296.76. This trade represents a 50.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 17,303 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the sale, the insider now owns 193,601 shares of the company’s stock, valued at approximately $9,319,952.14. This represents a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,097,578 shares of company stock valued at $38,080,320 in the last three months. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.